FDA Plans “Critical Path” Workshop On Prevention Therapies
This article was originally published in The Pink Sheet Daily
Two-day meeting will focus on both broad and disease-specific topics related to prevention development hurdles.
You may also be interested in...
FDA is planning to hold a public workshop designed to improve the development of biological products as part of its "Critical Path" initiative.
FDA is going to fund research projects aimed at eliminating barriers to product development as part of its "critical path" initiative
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.